CRMD
CorMedix Inc. Healthcare - Biotechnology Investor Relations →
CorMedix Inc. (CRMD) closed at $7.79 as of 2026-05-01, trading 16.4% above its 200-week moving average of $6.70. The stock moved further from the line this week, up from 11.2% last week. The 14-week RSI sits at 57, indicating neutral momentum.
Over the past 14 weeks, down-weeks have had more trading volume than up-weeks (0.69 buyers-vs-sellers ratio). That means when people are active, they're more often selling than buying. Sellers are still more in control than buyers.
Over the past 785 weeks of data, CRMD has crossed below its 200-week moving average 18 times. On average, these episodes lasted 26 weeks. The average one-year return after crossing below was -3.9%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $611 million, CRMD is a small-cap stock. The company generates a free cash flow yield of 17.8%, which is notably high. Return on equity stands at 66.6%, indicating strong profitability. The stock trades at 1.5x book value.
Share count has increased 85.1% over three years, indicating dilution. CRMD passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow. This stock also meets the Yartseva multibagger criteria as a small-cap with strong free cash flow yield and reasonable book value.
Over the past 15.1 years, a hypothetical investment of $100 in CRMD would have grown to $83, compared to $688 for the S&P 500. CRMD has returned -1.2% annualized vs 13.6% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: CRMD vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After CRMD Crosses Below the Line?
Across 17 historical episodes, buying CRMD when it crossed below its 200-week moving average produced an average return of -7.2% after 12 months (median -25.0%), compared to +13.1% for the S&P 500 over the same periods. 29% of those episodes were profitable after one year. After 24 months, the average return was -31.3% vs +32.2% for the index.
Each line shows $100 invested at the moment CRMD crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
CRMD has crossed below its 200-week MA 18 times with an average 1-year return of +-3.9% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Apr 2011 | Apr 2011 | 1 | 0.8% | -79.5% | -11.5% |
| May 2011 | Dec 2013 | 137 | 85.1% | -82.9% | -8.4% |
| Dec 2015 | Dec 2015 | 1 | 2.1% | -5.4% | -15.3% |
| Jan 2016 | Feb 2016 | 8 | 35.7% | +6.1% | -5.6% |
| Jun 2016 | Sep 2016 | 14 | 32.9% | -80.0% | -27.5% |
| Oct 2016 | Jan 2019 | 120 | 91.8% | -72.2% | -32.3% |
| Feb 2019 | Feb 2019 | 1 | 1.1% | -25.4% | -7.8% |
| May 2019 | Jun 2019 | 3 | 10.6% | -36.3% | +13.2% |
| Sep 2019 | Dec 2019 | 11 | 22.0% | -22.2% | +16.6% |
| Jan 2020 | Feb 2020 | 1 | 0.2% | +37.8% | +22.7% |
| Feb 2020 | Jun 2020 | 14 | 54.2% | +188.5% | +49.8% |
| Jul 2020 | Sep 2020 | 8 | 24.0% | +30.6% | +75.1% |
| Oct 2020 | Nov 2020 | 1 | 1.5% | -3.8% | +54.3% |
| Jul 2021 | Aug 2021 | 1 | 0.5% | -7.9% | +34.1% |
| Aug 2021 | Aug 2021 | 1 | 0.2% | -33.4% | +32.7% |
| Sep 2021 | Apr 2024 | 135 | 56.2% | -19.7% | +68.3% |
| May 2024 | Aug 2024 | 14 | 25.7% | +139.8% | +52.1% |
| Mar 2026 | Mar 2026 | 3 | 4.9% | N/A | +20.6% |
| Average | 26 | — | +-3.9% | — |
Frequently Asked Questions
Is CRMD below its 200-week moving average?
No. CorMedix Inc. (CRMD) is currently 16.4% above its 200-week moving average of $6.70. It would need to fall to $6.70 to cross below the line.
What is CRMD's 200-week moving average price?
CorMedix Inc.'s 200-week moving average is $6.70 as of 2026-05-01. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when CRMD drops below its 200-week moving average?
CRMD has crossed below its 200-week moving average 18 times in our data. The average one-year return after these crossings was -3.9%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 26 weeks on average.
Is CRMD a good value right now?
Here's what our data says about CRMD as of 2026-05-01: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 57. Free cash flow yield is 17.8%. Return on equity is 66.6%. Price-to-book is 1.5x. This is not a buy or sell recommendation — always do your own research.
How does CRMD compare to the S&P 500?
Over the past 15.1 years, $100 invested in CRMD would have grown to $83, compared to $688 for the S&P 500. That's -1.2% annualized vs 13.6% for the index. CRMD has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-05-01